

Table 8. NEUROINFLAMMATION AND CYTOKINE-TARGETED INTERVENTIONS : Targeting Complement System

Target	Drug	Main Indications	CT Number , Title, Study Protocol	Neurological Implications
Complement System	Eculizumab Anti-C5 antibody	<ul style="list-style-type: none"> • Paroxysmal nocturnal hemoglobinuria • Atypical hemolytic uremic syndrome • Generalized myasthenia gravis • Neuromyelitis optica spectrum disorder 	NCT04346797 CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort (CORIMUNO19-ECU) Interventional Phase 2	<p>Approved for neuromyelitis optica (Carparini et al., 2019), and myasthenia gravis (Frampton, 2020).</p> <p>Effective in patients with a genetic demyelinating neuropathy caused by CD59 mutation (Mevorach et al., 2016).</p> <p>It may aggravate progressive multifocal leukoencephalopathy caused by JC polyomavirus (Gomez-Cabeira et al., 2016).</p>
			NCT04355494 SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19 Expanded Access	
			NCT04288713 Eculizumab (Soliris) in Covid-19 Infected Patients (SOLID-C19) Expanded Access	